InsiderClue
Stocks · Health care · Biological Products, (No Diagnostic Substances)

Editas Medicine, Inc.

EDIT Clue Score47
United States Fiscal year ends December CIK 0001650664 Results filed 5 Aug 2026
Add to watchlist

What the insiders did Scheduled selling only

Individual transactions

14
Insider
Date
Role
Action
Shares
Price
Amount
Gilmore Neil O'Neill
3 Sep 2026
CEO
Sold on a plan
5,124
$3.04
$15.56K
Amy Parison
3 Sep 2026
SVP, Chief Financial Officer
Sold on a plan
453
$3.04
$1.38K
Linda Burkly
3 Sep 2026
EVP, Chief Scientific Officer
Sold on a plan
709
$3.04
$2.15K
Amy Parison
3 Aug 2026
SVP, Chief Financial Officer
Sold on a plan
678
$2.58
$1.75K
Linda Burkly
28 Jul 2026
EVP, Chief Scientific Officer
Sold on a plan
4,928
$2.67
$13.16K
Linda Burkly
3 Jun 2026
EVP, Chief Scientific Officer
Sold on a plan
731
$2.70
$1.97K
Gilmore Neil O'Neill
3 Jun 2026
CEO
Sold on a plan
15,380
$2.70
$41.54K
Amy Parison
3 Jun 2026
SVP, Chief Financial Officer
Sold on a plan
464
$2.70
$1.25K
Linda Burkly
3 Mar 2026
EVP, Chief Scientific Officer
Sold on a plan
749
$2.02
$1.51K
Amy Parison
3 Mar 2026
SVP, Chief Financial Officer
Sold on a plan
474
$2.02
$957.48
Gilmore Neil O'Neill
3 Mar 2026
CEO
Sold on a plan
5,394
$2.02
$10.89K
Amy Parison
3 Dec 2025
SVP, Chief Financial Officer
Sold on a plan
461
$2.15
$992.58
Gilmore Neil O'Neill
3 Dec 2025
CEO
Sold on a plan
5,603
$2.15
$12.06K
Linda Burkly
3 Dec 2025
EVP, Chief Scientific Officer
Sold on a plan
713
$2.15
$1.54K
Show all 14 transactions →

What was left out

Form 4 filings counted 24
Amendments (4/A) skipped 0
Filings about a different issuer 0
Unreadable filings 0
Joint filings 0
Sales on a Rule 10b5-1 plan 14
Sales straight out of an exercise 0
Sales at will 0
Transactions with no price 0
Shares from compensation/vesting 0
History held since 4 Feb 2016